Atherosclerosis Therapeutics Market 2027 by Type, End User and Geography | The Insight Partners

Atherosclerosis Therapeutics Market Forecast to 2027 - Covid-19 Impact and Global Analysis - by Type (Anti-platelet medications, Cholesterol lowering medications, Beta blockers, Angiotensin-converting enzyme (ACE) inhibitors, Calcium channel blockers, Others); End User (Hospital, Ambulatory Surgical Centers, Others) and Geography

Report Code: TIPRE00008170 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Atherosclerosis is hardening of artery due to the saturation of plaque inside the artery. The artery becomes narrow due to the development of plaque which eventually decreases the flow of blood to body parts. This further leads to elasticity loss of the walls of the arteries. Endothelium cells lined in thin layer which form the wall of arteries. Smoking, high cholesterol, and high blood pressure causes damage of endothelium which ultimately leads to atherosclerosis.

MARKET DYNAMICS

Rising geriatric population, and obesity, adoption of unhealthy diets leading to the incidence of high cholesterol, tobacco smoking, high body mass index, sedentary lifestyles, and hypertension are driving the Atherosclerosis Therapeutics market.

MARKET SCOPE

The "Global Atherosclerosis Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of Atherosclerosis Therapeutics market with detailed market segmentation by type, end user, and geography. The global Atherosclerosis Therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Atherosclerosis Therapeutics market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global Atherosclerosis Therapeutics market is segmented on the type, end user. Based on type, the market is segmented into Anti-platelet medications, Cholesterol lowering medications, Beta blockers, Angiotensin-converting enzyme (ACE) inhibitors, Calcium channel blockers, Others. Based on end user, the market is segmented into Hospital, Ambulatory Surgical Centers, Others.




Get more information on this report :

REGIONAL FRAMEWORK


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Atherosclerosis Therapeutics market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Atherosclerosis Therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Atherosclerosis Therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Atherosclerosis Therapeutics market in these regions.




Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Atherosclerosis Therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Atherosclerosis Therapeutics market are anticipated to lucrative growth opportunities in the future with the rising demand for Atherosclerosis Therapeutics market in the global market. Below mentioned is the list of few companies engaged in the Atherosclerosis Therapeutics market.

The report also includes the profiles of key Atherosclerosis Therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  Novartis AG
  •  Merck and Co., Inc.
  •  Sanofi
  •  F. Hoffmann-La Roche Ltd.
  •  GlaxoSmithKline plc
  •  Isis Pharmaceuticals, Inc.
  •  Anthera Pharmaceuticals
  •  Bayer AG
  •  Johnson and Johnson
  •  Cardium Therapeutics
  •  AstraZeneca Plc

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Atherosclerosis Therapeutics Market - By Type
1.3.2 Atherosclerosis Therapeutics Market - By End User
1.3.3 Atherosclerosis Therapeutics Market - By Region
1.3.3.1 By Country

2. KEY TAKEAWAYS


3. RESEARCH METHODOLOGY


4. ATHEROSCLEROSIS THERAPEUTICS MARKET LANDSCAPE

4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. ATHEROSCLEROSIS THERAPEUTICS MARKET - KEY MARKET DYNAMICS

5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC

6. ATHEROSCLEROSIS THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS

6.1. ATHEROSCLEROSIS THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. ATHEROSCLEROSIS THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE

7. ATHEROSCLEROSIS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - TYPE

7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. ANTI-PLATELET MEDICATIONS
7.3.1. Overview
7.3.2. Anti-platelet medications Market Forecast and Analysis
7.4. CHOLESTEROL LOWERING MEDICATIONS
7.4.1. Overview
7.4.2. Cholesterol lowering medications Market Forecast and Analysis
7.5. BETA BLOCKERS
7.5.1. Overview
7.5.2. Beta blockers Market Forecast and Analysis
7.6. ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS
7.6.1. Overview
7.6.2. Angiotensin-converting enzyme (ACE) inhibitors Market Forecast and Analysis
7.7. CALCIUM CHANNEL BLOCKERS
7.7.1. Overview
7.7.2. Calcium channel blockers Market Forecast and Analysis
7.8. OTHERS
7.8.1. Overview
7.8.2. Others Market Forecast and Analysis

8. ATHEROSCLEROSIS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - END USER

8.1. OVERVIEW
8.2. END USER MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL
8.3.1. Overview
8.3.2. Hospital Market Forecast and Analysis
8.4. AMBULATORY SURGICAL CENTERS
8.4.1. Overview
8.4.2. Ambulatory Surgical Centers Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis

9. ATHEROSCLEROSIS THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS

9.1. NORTH AMERICA
9.1.1 North America Atherosclerosis Therapeutics Market Overview
9.1.2 North America Atherosclerosis Therapeutics Market Forecasts and Analysis
9.1.3 North America Atherosclerosis Therapeutics Market Forecasts and Analysis - By Type
9.1.4 North America Atherosclerosis Therapeutics Market Forecasts and Analysis - By End User
9.1.5 North America Atherosclerosis Therapeutics Market Forecasts and Analysis - By Countries
9.1.5.1 United States Atherosclerosis Therapeutics Market
9.1.5.1.1 United States Atherosclerosis Therapeutics Market by Type
9.1.5.1.2 United States Atherosclerosis Therapeutics Market by End User
9.1.5.2 Canada Atherosclerosis Therapeutics Market
9.1.5.2.1 Canada Atherosclerosis Therapeutics Market by Type
9.1.5.2.2 Canada Atherosclerosis Therapeutics Market by End User
9.1.5.3 Mexico Atherosclerosis Therapeutics Market
9.1.5.3.1 Mexico Atherosclerosis Therapeutics Market by Type
9.1.5.3.2 Mexico Atherosclerosis Therapeutics Market by End User
9.2. EUROPE
9.2.1 Europe Atherosclerosis Therapeutics Market Overview
9.2.2 Europe Atherosclerosis Therapeutics Market Forecasts and Analysis
9.2.3 Europe Atherosclerosis Therapeutics Market Forecasts and Analysis - By Type
9.2.4 Europe Atherosclerosis Therapeutics Market Forecasts and Analysis - By End User
9.2.5 Europe Atherosclerosis Therapeutics Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Atherosclerosis Therapeutics Market
9.2.5.1.1 Germany Atherosclerosis Therapeutics Market by Type
9.2.5.1.2 Germany Atherosclerosis Therapeutics Market by End User
9.2.5.2 France Atherosclerosis Therapeutics Market
9.2.5.2.1 France Atherosclerosis Therapeutics Market by Type
9.2.5.2.2 France Atherosclerosis Therapeutics Market by End User
9.2.5.3 Italy Atherosclerosis Therapeutics Market
9.2.5.3.1 Italy Atherosclerosis Therapeutics Market by Type
9.2.5.3.2 Italy Atherosclerosis Therapeutics Market by End User
9.2.5.4 Spain Atherosclerosis Therapeutics Market
9.2.5.4.1 Spain Atherosclerosis Therapeutics Market by Type
9.2.5.4.2 Spain Atherosclerosis Therapeutics Market by End User
9.2.5.5 United Kingdom Atherosclerosis Therapeutics Market
9.2.5.5.1 United Kingdom Atherosclerosis Therapeutics Market by Type
9.2.5.5.2 United Kingdom Atherosclerosis Therapeutics Market by End User
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Atherosclerosis Therapeutics Market Overview
9.3.2 Asia-Pacific Atherosclerosis Therapeutics Market Forecasts and Analysis
9.3.3 Asia-Pacific Atherosclerosis Therapeutics Market Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Atherosclerosis Therapeutics Market Forecasts and Analysis - By End User
9.3.5 Asia-Pacific Atherosclerosis Therapeutics Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Atherosclerosis Therapeutics Market
9.3.5.1.1 Australia Atherosclerosis Therapeutics Market by Type
9.3.5.1.2 Australia Atherosclerosis Therapeutics Market by End User
9.3.5.2 China Atherosclerosis Therapeutics Market
9.3.5.2.1 China Atherosclerosis Therapeutics Market by Type
9.3.5.2.2 China Atherosclerosis Therapeutics Market by End User
9.3.5.3 India Atherosclerosis Therapeutics Market
9.3.5.3.1 India Atherosclerosis Therapeutics Market by Type
9.3.5.3.2 India Atherosclerosis Therapeutics Market by End User
9.3.5.4 Japan Atherosclerosis Therapeutics Market
9.3.5.4.1 Japan Atherosclerosis Therapeutics Market by Type
9.3.5.4.2 Japan Atherosclerosis Therapeutics Market by End User
9.3.5.5 South Korea Atherosclerosis Therapeutics Market
9.3.5.5.1 South Korea Atherosclerosis Therapeutics Market by Type
9.3.5.5.2 South Korea Atherosclerosis Therapeutics Market by End User
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Atherosclerosis Therapeutics Market Overview
9.4.2 Middle East and Africa Atherosclerosis Therapeutics Market Forecasts and Analysis
9.4.3 Middle East and Africa Atherosclerosis Therapeutics Market Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Atherosclerosis Therapeutics Market Forecasts and Analysis - By End User
9.4.5 Middle East and Africa Atherosclerosis Therapeutics Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Atherosclerosis Therapeutics Market
9.4.5.1.1 South Africa Atherosclerosis Therapeutics Market by Type
9.4.5.1.2 South Africa Atherosclerosis Therapeutics Market by End User
9.4.5.2 Saudi Arabia Atherosclerosis Therapeutics Market
9.4.5.2.1 Saudi Arabia Atherosclerosis Therapeutics Market by Type
9.4.5.2.2 Saudi Arabia Atherosclerosis Therapeutics Market by End User
9.4.5.3 U.A.E Atherosclerosis Therapeutics Market
9.4.5.3.1 U.A.E Atherosclerosis Therapeutics Market by Type
9.4.5.3.2 U.A.E Atherosclerosis Therapeutics Market by End User
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Atherosclerosis Therapeutics Market Overview
9.5.2 South and Central America Atherosclerosis Therapeutics Market Forecasts and Analysis
9.5.3 South and Central America Atherosclerosis Therapeutics Market Forecasts and Analysis - By Type
9.5.4 South and Central America Atherosclerosis Therapeutics Market Forecasts and Analysis - By End User
9.5.5 South and Central America Atherosclerosis Therapeutics Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Atherosclerosis Therapeutics Market
9.5.5.1.1 Brazil Atherosclerosis Therapeutics Market by Type
9.5.5.1.2 Brazil Atherosclerosis Therapeutics Market by End User
9.5.5.2 Argentina Atherosclerosis Therapeutics Market
9.5.5.2.1 Argentina Atherosclerosis Therapeutics Market by Type
9.5.5.2.2 Argentina Atherosclerosis Therapeutics Market by End User

10. INDUSTRY LANDSCAPE

10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

11. ATHEROSCLEROSIS THERAPEUTICS MARKET, KEY COMPANY PROFILES

11.1. NOVARTIS AG
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. MERCK AND CO., INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. SANOFI
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. F. HOFFMANN-LA ROCHE LTD.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. GLAXOSMITHKLINE PLC
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. ISIS PHARMACEUTICALS, INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. ANTHERA PHARMACEUTICALS
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. BAYER AG
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. JOHNSON AND JOHNSON
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. CARDIUM THERAPEUTICS
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
11.11. ASTRAZENECA PLC
11.11.1. Key Facts
11.11.2. Business Description
11.11.3. Products and Services
11.11.4. Financial Overview
11.11.5. SWOT Analysis
11.11.6. Key Developments

12. APPENDIX

12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Novartis AG
2. Merck and Co., Inc.
3. Sanofi
4. F. Hoffmann-La Roche Ltd.
5. GlaxoSmithKline plc
6. Isis Pharmaceuticals, Inc.
7. Anthera Pharmaceuticals
8. Bayer AG
9. Johnson and Johnson
10. Cardium Therapeutics
11. AstraZeneca Plc ?
TIPRE00008170
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking